OncoMatch/Clinical Trials/NCT07472140

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Is NCT07472140 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including PARP inhibitor + Bevacizumab and PARP inhibitor for ovarian cancer.

Phase 2/3RecruitingN.N. Alexandrov National Cancer CentreNCT07472140Data as of May 2026

Treatment: PARP inhibitor + Bevacizumab · PARP inhibitor — This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify